**Avdeef 2001** A. Avdeef. (2001). Physicochemical profiling (solubility, permeability and charge state). *Current Topics in Medicinal Chemistry*, *1*(4), 277-351.

**Avdeef 2003** A. Avdeef. (2003). Absorption and drug development - Solubility, permeability, and charge state.

**Dayton 1963** P.G. Dayton, T.F. Yu, W. Chen, L. Berger, L.A. West, and A.B. Gutman.  (1963). The physiological disposition of probenecid, including renal clearance, in man, studied by an improved method for its estimation in biological material. *The Journal of pharmacology and experimental therapeutics*, *140*, 278-286. 

**Emanuelsson 1987** B.M. Emanuelsson, B. Beermann, and L.K. Paalzow. (1987). w. Non-linear elimination and protein binding
of probenecid. *European Journal of Clinical Pharmacology*. *32*(4), 395-401.

**Hansch 1995** C. Hansch, A. Leo, and D. Hoekman (1995). Exploring QSAR: hydrophobic, electronic, steric constants.

**Ito 2014**  Y. Ito, T. Fukami, T. Yokoi, and M. Nakajima (2014).  An orphan esterase ABHD10 modulates probenecid acyl glucuronidation in human liver. *Drug Metabolism and Disposition*, *42*(12), 2109-2116.

**Izumi 2016** S. Izumi, Y. Nozaki, T. Komori, O. Takenaka, K. Maeda, H. Kusuhara, and Y. Sugiyama (2016). Investigation of fluorescein derivatives as substrates of organic anion transporting polypeptide (OATP) 1B1 to develop sensitive fluorescence-based OATP1B1 inhibition assays. *Molecular Pharmaceutics*, *13*(2), 438-448.

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. (2016). Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. *CPT Pharmacometrics Syst Pharmacol*. Oct;5(10), 516-531.

**Landersdorfer 2009** C.B. Landersdorfer, C.M.J. Kirkpatrick, M. Kinzig, J.B. Bulitta, U. Holzgrabe, G.L. Drusano, and F. Sorgel. (2009). Competitive inhibition of renal tubular secretion of f gemifloxacin by probenecid. *Antimicrobial Agents and Chemotherapy*, *53*(9), 3902-3907.

**Landersdorfer 2010** C.B. Landersdorfer, C.M.J. Kirkpatrick, M. Kinzig, J.B. Bulitta, U. Holzgrabe, U. Jaehde, A. Reiter, K.G. NaberM. Rodamer and F. Sorgel. (2010). Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. *British journal of clinical pharmacology*, *69*(2), 167-78.

**Meyer 2012** Meyer M, Schneckener S, Ludewig B, Kuepfer L, Lippert J. (2012). Using expression data for quantification of active processes in physiologically based pharmacokinetic modeling. *Drug Metab Dispos*. May;40(5), 892-901.

**Nishimura 2003** Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. *Yakugaku Zasshi.* May;123(5), 369-75.

**Shen 2019** H. Shen, V.K. Holenarsipur, T.T. Mariappan, D.M. Drexler, J.L. Cantone, P. Rajanna, S. Singh Gautam, Y. Zhang, J. Gan, P.A. Shipkova, P. Marathe, and W.G. Humphreys. (2019). Evidence for the validity of pyridoxic acid (PDA) as a plasma-based endogenous probe for OAT1 and OAT3 function in healthy subjects. *Journal of Pharmacology and Experimental Therapeutics*, *368*(1), 136-145.

**Selen 1982** A. Selen, G.L. Amidon, and P.G. Wellingx. (1982). Pharmacokinetics of probenecid following oral doses to human volunteers. *Journal of Pharmaceutical Sciences*, *71*(11), 1238-1242.

**Smith 1980** D.E. Smith, W.L. Gee, D.C. Brater, E.T. Lin, and L.Z. Benet (1980). Preliminary evaluation of furosemide–probenecid interaction in humans. *Journal of Pharmaceutical Sciences*, *69*(5):571–75.

**Söderlind 2010** E. Söderlind, E. Karlsson, A. Carlsson, R. Kong, A. Lenz, S. Lindborg, and J.J. Sheng (2010). Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids. *Molecular pharmaceutics*, *7*(5), 1498-1507.

**Tsuruya 2016** Y. Tsuruya, K. Kato, Y. Sano, Y. Imamura, K. Maeda, Y. Kumagai, Y. Sugiyama, and H. Kusuhara (2016). Investigation of endogenous compounds applicable to drug-drug interaction studies involving the renal organic anion transporters, OAT1 and OAT3, in humans, *Drug Metabolism and Disposition*, *44*(12), 1825-1933.

**Vree 1992** T.B. Vree, E.W. Van Ewijk-Beneken Kolmer, E.W. Wuis, and Y.A. Hekster.  (1992). Capacity-limited renal glucuronidation of probenecid by humans. A pilot Vmax-finding study. *Pharmaceutisch weekblad. Scientific edition*, *14*(5), 325-331.

**Vree 1993** T.B. Vree, E.W. Van Ewijk-Beneken Kolmer, E.W. Wuis, Y.A. Hekster, and M.M. Broekman (1993). Interindividual variation in the capacity-limited renal glucuronidation of probenecid by humans. *Pharmacy world & science : PWS*, *15*(5), 197-202.

**Wiebe 2020** S.T. Wiebe, T. Giessmann, K. Hohl, S. Schmidt-Gerets, E. Hauel, A. Jambrecina, K. Bader, N. Ishiguro, M.E. Taub, A. Sharma, T. Ebner, G. Mikus, M.F. Fromm, F. Müller, and P. Stopfer (2020). Validation of a drug transporter probe cocktail using the prototypical inhibitors rifampin, probenecid, verapamil, and cimetidine. *Clinical Pharmacokinetics*.

**Willmann 2007** Willmann S, Höhn K, Edginton A, Sevestre M, Solodenko J, Weiss W, Lippert J, Schmitt W. (2007). Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. *J Pharmacokinet Pharmacodyn.* 34(3), 401-431.

**Wishart 2006** D.S. Wishart, C. Knox, A.C. Guo, S. Shrivastava, M. Hassanali, P. Stothard, Z. Chang, and J. Woolsey (2006). DrugBank: a comprehensive resource for in silico drug discovery and exploration. *Nucleic acids research*, *34*, D668-72.


